Product Description
Mechanisms of Action: ROCK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Coronary Artery Disease|Microvascular Angina|Angina, Stable|Myocardial Ischemia|Erectile Dysfunction
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ACT14656 | P2 |
Terminated |
Coronary Artery Disease|Myocardial Ischemia|Microvascular Angina|Angina, Stable |
2018-07-23 |
|
2016-000629-38 | P2 |
Completed |
Coronary Artery Disease |
2018-07-23 |
|
RHOKET | P2 |
Completed |
Erectile Dysfunction |
2009-09-01 |